$RPHM
Reneo Pharmaceuticals Inc

2021 Q4 Form 10-K Financial Statement

#000155837022004158 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.524M $11.65M $1.130M
YoY Change 211.86% 222.71%
% of Gross Profit
Research & Development $7.100M $28.17M $5.120M
YoY Change 38.67% 76.67%
% of Gross Profit
Depreciation & Amortization $17.00K $50.00K $10.00K
YoY Change 70.0% 35.14%
% of Gross Profit
Operating Expenses $10.62M $39.82M $6.250M
YoY Change 69.98% 103.65%
Operating Profit -$39.82M
YoY Change 103.65%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $17.00K $50.00K $0.00
YoY Change -44.44%
Pretax Income -$10.61M -$39.77M -$6.250M
YoY Change 69.71% 104.32%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$10.61M -$39.80M -$6.250M
YoY Change 69.71% 104.47%
Net Earnings / Revenue
Basic Earnings Per Share -$2.19
Diluted Earnings Per Share -$433.0K -$2.19 -$0.26
COMMON SHARES
Basic Shares Outstanding 24.42M 18.14M
Diluted Shares Outstanding 18.14M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $147.7M $147.7M
YoY Change 175.56%
Cash & Equivalents $124.7M $124.7M $53.61M
Short-Term Investments $23.01M $23.00M
Other Short-Term Assets $6.064M $6.100M
YoY Change 335.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $153.7M $153.7M $55.03M
YoY Change 179.39% 179.45%
LONG-TERM ASSETS
Property, Plant & Equipment $212.0K $200.0K $69.00K
YoY Change 207.25% 100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $78.00K $100.0K $127.0K
YoY Change -38.58% 0.0%
Total Long-Term Assets $290.0K $300.0K $196.0K
YoY Change 47.96% 50.0%
TOTAL ASSETS
Total Short-Term Assets $153.7M $153.7M $55.03M
Total Long-Term Assets $290.0K $300.0K $196.0K
Total Assets $154.0M $154.0M $55.22M
YoY Change 178.92% 178.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.022M $2.000M $908.0K
YoY Change 122.69% 122.22%
Accrued Expenses $4.180M $4.200M $3.672M
YoY Change 13.83% 13.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.202M $6.200M $4.580M
YoY Change 35.41% 34.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $167.0K $600.0K
YoY Change
Total Long-Term Liabilities $167.0K $600.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.202M $6.200M $4.580M
Total Long-Term Liabilities $167.0K $600.0K
Total Liabilities $6.813M $6.800M $4.616M
YoY Change 47.6% 47.83%
SHAREHOLDERS EQUITY
Retained Earnings -$84.73M -$44.96M
YoY Change 88.46%
Common Stock $3.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $147.2M $147.2M -$42.12M
YoY Change
Total Liabilities & Shareholders Equity $154.0M $154.0M $55.22M
YoY Change 178.92% 178.99%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$10.61M -$39.80M -$6.250M
YoY Change 69.71% 104.47%
Depreciation, Depletion And Amortization $17.00K $50.00K $10.00K
YoY Change 70.0% 35.14%
Cash From Operating Activities -$10.02M -$38.00M -$5.410M
YoY Change 85.23% 105.01%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K $198.0K $10.00K
YoY Change -1000.0% 725.0%
Acquisitions
YoY Change
Other Investing Activities $8.243M -$23.18M $0.00
YoY Change -413.24%
Cash From Investing Activities $8.153M -$23.38M -$10.00K
YoY Change -81630.0% -416.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $84.61M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 119.0K 132.4M 47.19M
YoY Change -99.75% 180.09%
NET CHANGE
Cash From Operating Activities -10.02M -38.00M -5.410M
Cash From Investing Activities 8.153M -23.38M -10.00K
Cash From Financing Activities 119.0K 132.4M 47.19M
Net Change In Cash -1.749M 71.05M 41.77M
YoY Change -104.19% 96.74%
FREE CASH FLOW
Cash From Operating Activities -$10.02M -$38.00M -$5.410M
Capital Expenditures -$90.00K $198.0K $10.00K
Free Cash Flow -$9.931M -$38.20M -$5.420M
YoY Change 83.23% 105.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.19
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.60
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18143487
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2028198
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
CY2021Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.2235
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001637715
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2053070
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40315
CY2021 dei Entity Registrant Name
EntityRegistrantName
RENEO PHARMACEUTICALS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2309515
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
18575 Jamboree Road, Suite 275-S
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Irvine
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92612
CY2021 dei City Area Code
CityAreaCode
619
CY2021 dei Local Phone Number
LocalPhoneNumber
733-3852
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 Par Value per Share
CY2021 dei Trading Symbol
TradingSymbol
RPHM
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-42115000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
154024000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55221000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24455390
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2053070
CY2021Q2 dei Entity Public Float
EntityPublicFloat
93281340
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24458550
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California, United States
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
124660000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53613000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
23010000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6064000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1412000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
153734000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
55025000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
212000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127000
CY2021Q4 us-gaap Assets
Assets
154024000
CY2020Q4 us-gaap Assets
Assets
55221000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2022000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
908000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3672000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6202000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4580000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
167000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
36000
CY2021Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
444000
CY2021Q4 us-gaap Liabilities
Liabilities
6813000
CY2020Q4 us-gaap Liabilities
Liabilities
4616000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
105000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24457838
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
231902000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2843000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84728000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44958000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
34000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
147211000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28169000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15944000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11649000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3608000
CY2021 us-gaap Operating Expenses
OperatingExpenses
39818000
CY2020 us-gaap Operating Expenses
OperatingExpenses
19552000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-39818000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-19552000
CY2021 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
48000
CY2020 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
87000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39770000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19465000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39736000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19468000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.19
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.60
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18143487
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2028198
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-23127000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
393000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
87000
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19465000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-42115000
CY2021 rphm Convertible Preferred Stock Value Issued Upon Conversion
ConvertiblePreferredStockValueIssuedUponConversion
140078000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
84533000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3891000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
507000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
53000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39770000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
34000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
147211000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39770000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-19465000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
37000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-202000
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
17000
CY2021 rphm Fair Value Changes Of Share Based Performance Award
FairValueChangesOfShareBasedPerformanceAward
444000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3891000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
393000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1780000
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1486000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4711000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
967000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37983000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18536000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
198000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
24000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
31406000
CY2021 rphm Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
131000
CY2020 rphm Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
-5000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
8228000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
7400000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23376000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7376000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
84612000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
556000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
87000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132406000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
47272000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
71047000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
36112000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53613000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17501000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
124660000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53613000
CY2021 rphm Vesting Of Unvested Exercised Options
VestingOfUnvestedExercisedOptions
4000
CY2020 rphm Unpaid Convertible Preferred Stock Issuance Costs
UnpaidConvertiblePreferredStockIssuanceCosts
117000
CY2020 rphm Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
33000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5000
CY2021Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On April 5, 2021, the Company effected a 1-for-4.4748 reverse stock split of its common stock. The par value and the authorized number of shares of the common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the Series A and Series B convertible preferred stock conversion prices to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion. The accompanying consolidated financial statements and notes to the consolidated financial statements give retroactive effect to the reverse stock split for all periods presented.
CY2021Q4 rphm Cash And Cash Equivalents At Carrying Value And Short Term Investments
CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments
147700000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84700000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-39800000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38000000.0
CY2021Q4 rphm Cash And Cash Equivalents At Carrying Value And Short Term Investments
CashAndCashEquivalentsAtCarryingValueAndShortTermInvestments
147700000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The preparation of the Company’s consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure in the Company’s consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p>
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-300000
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
100000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4515143
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11604769
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-590000
CY2021 rphm Changed In Fair Value Of Share Based Performance Award
ChangedInFairValueOfShareBasedPerformanceAward
-146000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
444000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
345000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
152000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
133000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
83000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
212000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000
CY2021Q4 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
1236000
CY2020Q4 rphm Accrued Clinical And Regulatory Expenses
AccruedClinicalAndRegulatoryExpenses
1019000
CY2021Q4 rphm Accrued Development Expenses
AccruedDevelopmentExpenses
1482000
CY2020Q4 rphm Accrued Development Expenses
AccruedDevelopmentExpenses
1443000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1027000
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
888000
CY2021Q4 rphm Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
435000
CY2020Q4 rphm Accrued Other Research And Development Expenses
AccruedOtherResearchAndDevelopmentExpenses
322000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4180000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3672000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11400000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0100
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.783
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5719844
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
935478
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.56
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3537885
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.03
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
238515
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.13
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
19205
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.54
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4215643
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.49
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
13530000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1179617
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.84
CY2021 rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P7Y1M6D
CY2021 rphm Share Based Compensation Arrangement By Share Based Payment Award Options Vested Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedIntrinsicValue
5553000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2695756
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.50
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8089000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0088
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.717
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3469000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
3316000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
35000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.312
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3891000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
393000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-39718000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21291000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-52000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1826000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-39770000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19465000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13446000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6488000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2155000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
663000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
653000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
179000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
24000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
104000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19864000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
10671000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19864000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10662000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
9000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 rphm Effective Income Tax Rate Reconciliation Research And Development True Up
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTrueUp
-0.001
CY2020 rphm Effective Income Tax Rate Reconciliation Research And Development True Up
EffectiveIncomeTaxRateReconciliationResearchAndDevelopmentTrueUp
0.065
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.018
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.035
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.022
CY2021 rphm Effective Income Tax Rate Reconciliation Global Intangible Low Taxed Income
EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome
-0.005
CY2020 rphm Effective Income Tax Rate Reconciliation Global Intangible Low Taxed Income
EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome
-0.002
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.229
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
19900000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
258000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
168000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2741000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
90000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2999000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
258000
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
3000000.0
CY2020Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2021Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
501000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
430000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
322000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
332000
CY2021Q4 rphm Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
313000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1898000

Files In Submission

Name View Source Status
0001558370-22-004158-index-headers.html Edgar Link pending
0001558370-22-004158-index.html Edgar Link pending
0001558370-22-004158.txt Edgar Link pending
0001558370-22-004158-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rphm-20211231.xsd Edgar Link pending
rphm-20211231x10k.htm Edgar Link pending
rphm-20211231x10k001.jpg Edgar Link pending
rphm-20211231x10k002.jpg Edgar Link pending
rphm-20211231x10k003.jpg Edgar Link pending
rphm-20211231x10k004.jpg Edgar Link pending
rphm-20211231x10k005.jpg Edgar Link pending
rphm-20211231x10k006.jpg Edgar Link pending
rphm-20211231x10k007.jpg Edgar Link pending
rphm-20211231x10k008.jpg Edgar Link pending
rphm-20211231x10k009.jpg Edgar Link pending
rphm-20211231x10k010.jpg Edgar Link pending
rphm-20211231x10k011.jpg Edgar Link pending
rphm-20211231x10k012.jpg Edgar Link pending
rphm-20211231x10k013.jpg Edgar Link pending
rphm-20211231x10k014.jpg Edgar Link pending
rphm-20211231x10k015.jpg Edgar Link pending
rphm-20211231x10k016.jpg Edgar Link pending
rphm-20211231x10k017.jpg Edgar Link pending
rphm-20211231x10k018.jpg Edgar Link pending
rphm-20211231x10k_htm.xml Edgar Link completed
rphm-20211231xex10d11.htm Edgar Link pending
rphm-20211231xex10d12.htm Edgar Link pending
rphm-20211231xex10d12001.jpg Edgar Link pending
rphm-20211231xex10d12002.jpg Edgar Link pending
rphm-20211231xex10d12003.jpg Edgar Link pending
rphm-20211231xex10d12013.jpg Edgar Link pending
rphm-20211231xex10d12016.jpg Edgar Link pending
rphm-20211231xex10d12017.jpg Edgar Link pending
rphm-20211231xex10d12018.jpg Edgar Link pending
rphm-20211231xex10d12024.jpg Edgar Link pending
rphm-20211231xex10d12026.jpg Edgar Link pending
rphm-20211231xex10d12028.jpg Edgar Link pending
rphm-20211231xex10d12029.jpg Edgar Link pending
rphm-20211231xex10d13.htm Edgar Link pending
rphm-20211231xex10d13001.jpg Edgar Link pending
rphm-20211231xex10d13003.jpg Edgar Link pending
rphm-20211231xex10d13004.jpg Edgar Link pending
rphm-20211231xex10d14.htm Edgar Link pending
rphm-20211231xex10d14001.jpg Edgar Link pending
rphm-20211231xex10d14002.jpg Edgar Link pending
rphm-20211231xex10d14003.jpg Edgar Link pending
rphm-20211231xex10d14004.jpg Edgar Link pending
rphm-20211231xex21d1.htm Edgar Link pending
rphm-20211231xex23d1.htm Edgar Link pending
rphm-20211231xex31d1.htm Edgar Link pending
rphm-20211231xex31d2.htm Edgar Link pending
rphm-20211231xex32d1.htm Edgar Link pending
rphm-20211231xex4d3.htm Edgar Link pending
rphm-20211231_cal.xml Edgar Link unprocessable
rphm-20211231_def.xml Edgar Link unprocessable
rphm-20211231_lab.xml Edgar Link unprocessable
rphm-20211231_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending